Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon
This article was originally published in The Pink Sheet Daily
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
You may also be interested in...
Boehringer Ingelheim submits type 2 diabetes therapy empagliflozin; Pozen seeks a partner to help it commercialize its aspirin/PPI combo following its NDA submission; Eisai gets FDA approval for pediatric use of acid reflux drug Aciphex; Merck announces FDA’s acceptance of its oral grass pollen allergy immunotherapy BLA; the EMA accepts Shionogi’s menopause drug Osphena for review, and IntelGenx submits an NDA for an oral film version of Maxalt-MLT.
Merck’s proposed Rx-to-OTC switch of Oxytrol for Women is about identifying symptoms of overactive bladder, not diagnosing the condition, says Eric Brass, former chair of FDA’s Nonprescription Drugs Advisory Committee. Several NDAC members Nov. 9 insisted OAB should be diagnosed before treatment.
A 14% decline in nutritional segment sales that slightly hampered Perrigo Co.’s consumer business revenue could affect the firm’s stock valuation if it cannot turn the division around, multiple analysts said. But Perrigo says the dip was expected and temporary,